Leo Pharma eczema treatment recommended in two UK countries
After postponing the decision in April, the British medicines council NICE has now ruled that Adtralza can be recommended to treat atopic dermatitis.
by christian bundgaard, translated by catherine brett
After months of back and forth, the National Institute for Health and Care Excellence (NICE) has decided that Leo Pharma’s monoclonal antibody Adtralza (tralokinumab) can be recommended as a treatment for moderate to severe eczema.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma appoints experienced Swedish national to board
For subscribers
Novo Nordisk and Leo Pharma seek permission to use oil
For subscribers
